Bravecto CombiUNO Chewable Tablets for Dogs (> 5.0 – 10.0 kg)

Parasites need to start feeding on the host to become exposed to fluralaner;
therefore the risk of the transmission of parasite borne diseases (including Babesia
canis canis and D. caninum) cannot be completely excluded.
Unnecessary use of antiparasitics or use deviating from the instructions given in the
SPC may increase the resistance selection pressure and lead to reduced efficacy.
The decision to use the veterinary medicinal product should be based on
confirmation of the parasitic species and burden, or of the risk of infestation based on
its epidemiological features, for each individual animal.
The possibility that other animals in the same household can be a source of re-
infection with parasites should be considered, and these should be treated as
necessary with an appropriate veterinary medicinal product.

Special precautions for safe use in the target species:
Use with caution in dogs with pre-existing epilepsy.
In the absence of available data, the veterinary medicinal product should not be used
on puppies less than 8 weeks old and /or dogs weighing less than 2 kg.
The veterinary medicinal product should not be administered at intervals shorter than
8 weeks as the safety for shorter intervals has not been tested.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals:
Keep the veterinary medicinal product in the original packaging until use, in order to
prevent children from getting direct access to the veterinary medicinal product.
Hypersensitivity reactions in humans have been reported.
Do not eat, drink or smoke while handling the veterinary medicinal product.
Wash hands thoroughly with soap and water immediately after use of the veterinary
medicinal product.
Special precautions for the protection of the environment:
Not applicable.
Other precautions:
Not applicable.

Revised: August 2025
AN: 00732/2025